NASDAQ:PGEN Precigen Q1 2025 Earnings Report $4.45 -0.08 (-1.77%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$4.50 +0.05 (+1.12%) As of 06/12/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Precigen EPS ResultsActual EPS-$0.07Consensus EPS -$0.08Beat/MissBeat by +$0.01One Year Ago EPSN/APrecigen Revenue ResultsActual Revenue$1.34 millionExpected Revenue$0.50 millionBeat/MissBeat by +$840.00 thousandYoY Revenue GrowthN/APrecigen Announcement DetailsQuarterQ1 2025Date5/14/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time4:00PM ETUpcoming EarningsPrecigen's Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Precigen Earnings HeadlinesPrecigen (PGEN) Stock Valuation Check As High P/B Multiple Meets Large DCF Upside EstimateJune 14 at 12:44 PM | uk.finance.yahoo.comIs Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?June 13 at 9:54 AM | finance.yahoo.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 14 at 1:00 AM | Behind the Markets (Ad)Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community VoicesJune 11 at 8:00 AM | prnewswire.comPrecigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comPrecigen (NASDAQ:PGEN) CEO Helen Sabzevari Sells 119,250 SharesJune 3, 2026 | americanbankingnews.comSee More Precigen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precigen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precigen and other key companies, straight to your email. Email Address About PrecigenPrecigen (NASDAQ:PGEN) (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects. The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products. By using a modular receptor system, OmniCAR T cells can be retargeted against multiple tumor antigens through the administration of different adaptor molecules. In addition, Precigen’s ActoBiotics platform engineers live bacterial strains to deliver therapeutic payloads at disease sites, offering a novel route to treat gastrointestinal and other localized disorders. Precigen’s clinical pipeline includes several early- to mid-stage programs. In oncology, the company is evaluating OmniCAR candidates targeting hematologic malignancies and solid tumors. The ActoBiotics pipeline features programs for inflammatory bowel disease and metabolic disorders. Precigen also maintains research collaborations and licensing partnerships aimed at expanding the utility of its gene control and vector technologies across diverse therapeutic areas. Originally founded in 1998 as Intrexon Corporation, the company rebranded as Precigen in 2020 to reflect its strategic focus on precision genetic medicine. Headquartered in Germantown, Maryland, Precigen operates research and manufacturing sites in the United States and Europe. Under the leadership of President and CEO Helen Sabzevari, PhD, the company continues to build its pipeline and advance next-generation therapies toward regulatory milestones and commercialization.View Precigen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationWhy Oracle's 10% Drop May Be Telling the Wrong StorySpotify's "North Star" Outlook Was Music to Investors EarsThis Energy Stock Has Quietly Soared 130% in a Year Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
